cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Catalent Inc
12 own
9 watching
Current Price
$53.65
$1.38
(2.64%)
logo-ctlt
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
9,657M
52-Week High
52-Week High
115.335
52-Week Low
52-Week Low
40.69
Average Volume
Average Volume
1.75M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
38.4575
iconMarket Capitalization9,657M
icon52-Week High115.335
icon52-Week Low40.69
iconAverage Volume1.75M
iconDividend Yield--
iconP/E Ratio38.4575
What does the Catalent Inc do?
Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics, and consumer health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment provides formulation, development, and manufacturing services for softgels, which are used in a range of customer products, including prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics. Its principal softgel technologies include traditional softgel capsules, and Vegicaps and OptiShell capsules. The Drug Delivery Solutions segment formulates, develops, and manufactures prescription, and consumer and animal health products using proprietary technologies, including OptiMelt, OptiPact, OptiForm, and Zydis, as well as other proprietary and conventional drug delivery technologies, such as prefilled syringes; manufactures blow-fill seal unit dose, including ADVASEPT technology; develops biologic cell line, including GPEx and SMARTag technologies; and provides analytical and bioanalytical development, and testing services, as well as offers respiratory products formulation and manufacturing, micronization and particle engineering, and regulatory consulting services. The Clinical Supply Services segment provides manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials for customer required patient kits. This segment also offers FastChain demand-led clinical supply services; clinical e-solutions and informatics; and comparator sourcing services. The company serves pharmaceutical and biotechnology companies; and consumer health companies, as well as companies in other healthcare market segments, such as animal health and medical devices, and companies in industries, including cosmetics. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.
Read More
How much money does Catalent Inc make?
News & Events about Catalent Inc.
Business Wire
8days ago
Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that it will release financial results for the second quarter of fiscal year...
PR Newswire
19days ago
Avantor and Catalent Enter into Multi-Year Supply and Services Agreement Avantor and Catalent Enter into Multi-Year Supply and Services Agreement PR Newswire RADNOR, Pa. and SOMERSET, N.J., Jan. 9, 2023 RADNOR, Pa. and SOMERSET, N.J., Jan. 9, 2023 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a...
Business Wire
1month ago
Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that current board member and lead independent director J. Martin (Marty...
Zolmax
2 months ago
Shares of Catalent, Inc. (NYSE:CTLT Get Rating) have been assigned a consensus recommendation of Hold from the thirteen ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and ...
Ticker Report
2 months ago
Catalent, Inc. (NYSE:CTLT Get Rating) Equities research analysts at William Blair reduced their Q2 2023 earnings per share (EPS) estimates for Catalent in a report issued on Wednesday, November 2nd. William Blair analyst M. Smock now forecasts that the company will earn $0.53 per ...
Frequently Asked Questions
Frequently Asked Questions
What is Catalent Inc share price today?
plus_minus_icon
Can Indians buy Catalent Inc shares?
plus_minus_icon
How can I buy Catalent Inc shares from India?
plus_minus_icon
Can Fractional shares of Catalent Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Catalent Inc stocks?
plus_minus_icon
What is today’s traded volume of Catalent Inc?
plus_minus_icon
What is today’s market capitalisation of Catalent Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Catalent Inc?
plus_minus_icon
What percentage is Catalent Inc down from its 52-Week High?
plus_minus_icon
What percentage is Catalent Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$53.65
$1.38
(2.64%)
logo-ctlt
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
$40.02
$0.64 (1.63 %)
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc.
$7.65
$-0.04 (-0.52 %)
United Therapeutics Corporation
United Therapeutics Corporation
$259.68
$-4.55 (-1.72 %)
Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals Inc
$52.02
$0.51 (0.99 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
$40.02
$0.64 (1.63 %)
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc.
$7.65
$-0.04 (-0.52 %)
United Therapeutics Corporation
United Therapeutics Corporation
$259.68
$-4.55 (-1.72 %)
Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals Inc
$52.02
$0.51 (0.99 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00